This is a working overview of Beta-NMN, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | −20 °C or below | Dry, desiccated, protected from light |
| Aqueous solubility | High | Stability is pH- and temperature-dependent |
| Identity method | NMR spectroscopy | Confirms structure and anomeric form |
| Purity method | HPLC-UV or LC-MS | Measures assay and related substances |
| Common salt forms | Free acid; sodium salt | Counterion changes mass and hygroscopicity |
Stability of NMN depends on physical form, temperature, moisture, light, and pH. The solid compound is generally more stable than aqueous solutions, which can degrade over time, especially when warm or exposed to extreme pH. Recommended laboratory storage is typically desiccated at −20 °C or below, protected from light, with containers sealed to limit moisture uptake. In solution, degradation products may include nicotinamide and related ribosides, and the rate varies with buffer composition and concentration. Analytical laboratories often prepare fresh solutions and validate stability for each method.
Quality control for NMN materials usually covers identity, assay purity, residual solvents, heavy metals, microbial limits, and moisture content. Certificates of analysis from suppliers may report high-performance liquid chromatography purity, mass spectrometry identity, and elemental impurity testing. Regulatory treatment differs by country: NMN is not an approved drug, and its status as a dietary supplement ingredient or novel food has been debated. Some authorities have restricted sales pending safety and regulatory review, while others allow it under specific categories. Buyers should verify documentation rather than rely on label claims.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
=== Adenovirus and cytomegalovirus === As of 2014, brincidofovir is in Phase III clinical trials for use in humans against cytomegalovirus and adenovirus. Preliminary safety data from a database of 1000 patients supported progression into later phase trials, Chimerix announced in December 2015 that the Phase III trials for use of the drug in preventing cytomegalovirus infection in stem cell transplant patients had failed, and in February 2016 shut down two other late-stage trials for use of the drug in preventing infection after kidney transplants. Brincidofovir is not yet FDA approved for adenovirus or cytomegalovirus due to lack of efficacy in clinical trials. In a trial of brincidofovir for CMV prophylaxis in stem cell transplant patients, brincidofovir was associated with a 15.5% week 24 all-cause mortality compared with 10.1% among placebo recipients. Additionally brincidofovir was associated with increased serious adverse events (57.1% versus 37.6%) compared with placebo. Brincidofovir was initially offered via an FDA expanded access trial; however as of 9 May 2019, Chimerix discontinued clinical trials of brincidofovir for the treatment of adenovirus and discontinued the expanded access program in 2019.
=== Approvals === Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. Viadur was approved by the FDA for palliative treatment of advanced prostate cancer on 6 March 2000. Eligard was approved by the FDA for palliative treatment of advanced prostate cancer on 24 January 2002. Fensolvi was approved by the FDA for children with central precocious puberty on 4 May 2020.
heat-shock protein (HSP) Any of a highly conserved family of proteins found in virtually all living organisms and expressed in response to a diverse variety of environmental stressors, including extreme heat or cold, ultraviolet radiation, and oxidative damage. These proteins primarily serve as molecular chaperones, stabilizing other proteins in order to ensure proper folding or to help refold those that have been damaged by the stress. Transcription of many HSP genes is dramatically upregulated as part of the heat shock response pathway.
Sources: en.wikipedia.org
Thyroid-stimulating hormone (TSH or thyrotropin) – stimulates the thyroid gland to make and release thyroid hormone. Adrenocorticotropic hormone (ACTH or corticotropin) – stimulates the adrenal cortex to release glucocorticoids. Luteinizing hormone (LH) – stimulates the release of steroid hormones in gonads—the ovary and testes. Follicle-stimulating hormone (FSH) – stimulates the maturation of eggs and production of sperm.
==== Ciprofloxacin ==== Due to the constraints and confined environments that astronauts are exposed to for long durations of time, they are at risk for higher rates of infection. Ciprofloxacin is a common drug used to treat infections, especially bacterial of nature, and is used to study antibiotics delivery in outer space due to its good bioavailability, infrequent dose intake, multiple-dose intake abilities (oral or intravenous), and stability. This study also employs a bed-rest model called the antiorthostatis bed rest (ABR) model, where subjects lie at a 12° angle downwards to simulate space flight weightlessness. Six individuals were employed to take one dose of 250 mg ciprofloxacin, once at weightlessness and once at normal conditions, separated between fifteen days. Blood was examined at intervals of 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, and 12 hours and urine samples were also collected at 0, 3, 6, 8, and 12 hours after each dose. It was found that ciprofloxacin's penetration in the tissue was lower in microgravity conditions than normal, indicating tissue penetration to be an issue in outer space for ciprofloxacin. In addition, compared to doses stored at ground versus in space, there was visible discoloration in samples stored in outer space and the expiration period in outer space was much shorter than on the ground.
==== Neutral loss scan ==== In the neutral loss scan method both Q1 and Q3 are scanned together, but with a constant mass offset. This allows the selective recognition of all ions which, by fragmentation in q2, lead to the loss of a given neutral fragment (e.g., H2O, NH3). Similar to the precursor ion scan, this method is useful in the selective identification of closely related compounds in a mixture.
== Pharmacodynamics == AM404 is a weak agonist of cannabinoid receptors CB1 and CB2, an inhibitor of endocannabinoid transporter, a potent activator of TRPV1, and a very potent inhibitor of Nav1.8 and 1.7. It weakly inhibits cyclooxygenases (COX). The endocannbinoid system, TRPV1, and COX are involved in pain and thermoregulatory pathways. Nav1.8 and 1.7 are involved in peripheral pain perception.
Sources: en.wikipedia.org
With war on-going in Ukraine, NATO and the US are showing renewed interest in the GIUK gap, positioning Denmark to be a key player in matters of broader European security and increasing the gap's strategic importance to the Danish Realm.
== Further reading == Boie F (1827). Bemerkungen über Merrem's Versuch eines Systems der Amphibien, 1te Lieferung: Ophidier. Isis von Oken 20: 508-566. (Cophias wagleri, new species, p. 562). (in German). Boulenger GA (1896). Catalogue of the Snakes in the British Museum (Natural History). Volume III., Containing the ... Viperidæ. London: Trustees of the British Museum (Natural History). (Taylor and Francis, printers). xiv + 727 pp. + Plates I-XXV. (Lachesis wagleri, pp. 562–564).
== Education == Foyer attended Portsmouth Polytechnic (now the University of Portsmouth) from 1971–74, achieving a BSc with Class II, Division I Honours in Biology (CNAA). From 1974–77 she attended the Department of Biochemistry, King's College London, where she completed her PhD. During this time Foyer also attended a course on immunology at Chelsea College, London. In 1998 Foyer was elected a Fellow of the Institute of Biology.
In 1993, the church was held liable for the first time (overturned on appeal), after 11-year-old Ian Lundman died of hyperglycemia in Minnesota in 1989. The church sent a Christian Science nurse to sit with him; doctors testified that he could have been saved by an insulin injection up to two hours before his death. The mother and stepfather were charged with manslaughter, but the charges were dismissed. The boy's father, Douglass Lundman, sued the mother, stepfather, practitioner, nurse, nursing home and church. He was awarded $5.2 million compensatory damages, later reduced to $1.5 million, and $9 million in punitive damages against the church. The Minnesota State Court of Appeals overturned the award against the church and nursing home in 1995, finding that a judgment that forced the church to "abandon teaching its central tenet" was unconstitutional, and that while the individuals had a duty of care toward the boy, the church and nursing home did not.
In 2019, upon identification of a causal relation between Allergan Biocell breast prostheses (with a textured surface) and an immune-system cancer [anaplastic, large-cell lymphoma (BIA-ALCL)], the FDA recalled every model of prosthetic breast made by the Allergan Biocell company.
Sources: en.wikipedia.org
Purity is commonly measured by high-performance liquid chromatography with ultraviolet or mass spectrometric detection. Nuclear magnetic resonance can confirm identity and anomeric composition. Water content and residual solvents may be tested separately.
Dry NMN is typically stored refrigerated or frozen in a desiccated container. Solutions are less stable and should be kept cold and used promptly. Protection from light and moisture helps limit degradation.
Beta-NMN is the naturally occurring anomer involved in NAD+ production. Alpha-NMN can form during synthesis and is often tracked as an impurity. Analytical methods such as NMR or HPLC can distinguish the two forms.
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.